Afternoon Market Losers
July 01, 2013 at 13:53 PM EDT
Insmed Incorp. (NASDAQ: INSM ) plunged 14.63% to $10.21 amid a Phase 3 trial of Arikace which met a primary endpoint, but a company slideshow which revealed competitor Novartis's (NYSE: NVS ) Tobi drug showed more favorable results. InterDigital (NASDAQ: IDCC ) dropped 12.83%
